Efficacy
Clinical Efficacy
Austria/Medical University of Vienna
Prof. A. PÜSPÖK, MD
Multi center study, 7 sites
Cholangiocarcinoma: (n=88)
150 consecutive applications
UEG J 2017 Feb; 5(1): 104-110
15.6 months (12.3–18.7) median survival
14 % cholangitis
0 photosensitivity
0 intra-procedural adverse events
0 procedure related mortality
Austria/Medical University Innsbruck
Prof. W. VOGEL, MD
cholangiocarcinoma, Klatskin,
esophageal cancer, Barrett’s,
colorectal cancer:
> 90 % clinical response:
shrinkage of tumor mass, size
reduction of degree of stenosis
50 % without post-procedural stenting
20 % cholangitis without any mortality
15,8 months (12,9 - 18,1) median survival with QoL
0,03 % sunburn/grade 1
0 % procedure related mortality
Sweden/University Hospital Lund
Prof. K. SVANBERG, MD
basal cell carcinoma:
75 % remission
no side effects
Austria/Rudolfstiftung Vienna
Prof. W. GRÜNBERGER, MD
cervical dysplasia:
80 % remission
no side effects
Austria/Medical University Vienna
Prof. H. HÖNIGSMANN, MD
actinic keratosis:
100 % clinical response
250 % higher tolerability (p<0.0001)
no side effects
Procedure Efficacy: Bile duct
| Chemotherapy* |
PHOTONIC
TUMOR
THERAPY
|
Efficacy
Advantage
|
|
| REIMBURSED | REIMBURSED | % | |
|
Cost
€
|
6.140,00 | 5.140,00 | 120 |
|
Clinical response
%
|
9,5 | >90 | 947 |
|
Median Survival
m
|
6,5 | 18,5 | 285 |
| RF-Ablation* | Mucosectomy* |
PHOTONIC
TUMOR
THERAPY
|
|
| REIMBURSED | REIMBURSED | REIMBURSED | |
Number of Procedures required |
3 - 4 | 2 - 3 | 1 |
Cost Procedure
€
|
9.000,00 | 750,00 | 5.140,00 |
Cost Hospitalization
€
|
7.500,00 | 6.250,00 | 1.000,00 |
|
Cost Over all
€
|
16.500,00 | 7.000,00 | 6.140,00 |
|
Cost Disadvantage
%
|
268 | 114 | 0 |
Procedure Efficacy: Esophagus